Tag: GlobeNewswire

AS Silvano Fashion Group Consolidated Interim Financial Report for Q3 and 09m of 2026

Selected Financial Indicators

Summarized selected financial indicators of the Group for 09 months of 2026 compared to 09 months of 2025 and 30.09.2026 compared to 31.12.2025 were as follows:

in thousands of EUR	09m 2026	09m 2025	Change
Revenue	44 722	44 379	0.8%
Gross Profit	25 217	24 230	4.1%
Operating profit	10 086	10 258	-1.7%
EBITDA	12 790	12 810	-0.2%
Net profit for the period	7 045	8 985	-21.6%
Net profit attributable equity holders of the Parent company	6 496	8 281	-21.6%
Earnings per share (EUR)	0,18	0,23	-21.7%
Operating cash flow for the period	14 533	6 866	111.7%
in thousands of EUR	30.09.2026	31.12.2025	Change
Total assets	98 164	93 847	4.6%
Total current assets	86 344	79 659	8.4%
Total equity attributable to equity holders of the Parent company	82 338	76 768	7.3%
Cash and cash equivalents	16 906	6 639	154.6%
Short-term deposits over 3 months	39 117	38 311	2.1%
Margin analysis, %	09m 2026	09m 2025	Change
Gross profit	56.4	54.6	3.3%
Operating profit	22.6	23.1	-2.2%
EBITDA	28.6	28.9	-1.0%
Net profit	15.8	20.2	-21.8%
Net profit attributable to equity holders of the Parent company	14.5	18.7	-22.5%
Financial ratios, %	30.09.2026	31.12.2025	Change
ROA	7.7	10.0	-23.0%
ROE	9.3	12.5	-25.6%
Price to earnings ratio (P/E)	5.3	4.9	8.2%
Current ratio	12.4	8.6	44.2%
Quick ratio	8.6	5.2	65.4%

Financial performance

The Group`s sales amounted 44 722 thousand EUR during 09 months of 2026, representing a 0.8% increase as compared to the same period of previous year. Overall, retail increased by 12.8%, measured in EUR.

The Group’s gross profit during 09 months of 2026 amounted to 25 217 thousand EUR and increase by 4.1% compared to previous year. The gross margin during 09 months of 2026 increased by 3.3% compared to 09 months of 2025. The cost of sold goods decreased by 3.2%.

Consolidated operating profit for 09 months of 2026 amounted to 10 086 thousand EUR, compared to 10 258 thousand EUR for 09 months of 2025, decrease by 1.7%. The consolidated operating profit margin was 22.6% for 09 months of 2026 (23.1% for 09 months of 2025). Consolidated EBITDA for 09 months of 2026 decreased by 0.2% and amounted to 12 790 thousand EUR, which is 28.6% in margin terms (12 810 thousand EUR and 28.9% for 09 months of 2025).

Reported consolidated net profit attributable to equity holders of the Parent company for 09 months of 2026 amounted 6 496 thousand EUR, compared to net profit of 8 281 thousand EUR for 09 months of 2025, net profit margin attributable to equity holders of the Parent company for 09 months of 2026 was 14.5% against net profit margin 18.7% for 09 months of 2025.

Financial position

As of 30 September 2026, consolidated assets amounted to 98 164 thousand EUR representing increase by 4.6% as compared to the position as of 31 December 2025.

Trade and other receivables increased by 524 thousand EUR as compared to 31 December 2025 and amounted to        1 853 thousand EUR as of 30 September 2026. Inventory balance decreased by 4 928 thousand EUR and amounted to 26 309 thousand EUR as of 30 September 2026.

Equity attributable to equity holders of the Parent company increased by 5 570 thousand EUR and amounted to             82 338 thousand EUR as of 30 September 2026. Current liabilities decreased by 2 316 thousand EUR during 09 months of 2026.

Investments

During 09 months of 2026 the Group’s investments into property, plant and equipment totalled 164 thousand EUR, in previous year same 562 thousand EUR. Investments were made mainly into opening and renovating own stores, as well into equipment and facilities to maintain effective production for future periods.

Personnel

As of 30 September 2026, the Group employed 1 561 employees, including 539 people in retail operations. The rest were employed in production, wholesale, administration and support operations. In 31.12.2025 there were 1 639 employees, including 552 people in retail operations.

Total salaries and related taxes during 09 months  of 2026 amounted 12 844 thousand EUR (11 648 thousand EUR in 09 months 2025). The remuneration of key management of the Group, including the key executives of all subsidiaries, totalled 1 052 thousand EUR.

Consolidated Statement of Financial Position

in thousands of EUR	Note	30.09.2026	31.12.2025
		Unaudited	Audited
ASSETS
Current assets
Cash and cash equivalents	2	16 906	6 639
Short-term deposits over 3 months	2	39 117	38 311
Trade and other receivables	3	1 853	1 329
Prepayments and other tax receivables	3	2 114	2 106
Other assets		45	37
Inventories	4	26 309	31 237
Total current assets		86 344	79 659
Non-current assets
Non-current receivables		307	313
Investments in associates		92	97
Investments in other shares		220	221
Deferred tax asset		3 052	3 656
Intangible assets		634	658
Investment property		833	859
Property, plant and equipment	5	6 682	8 384
Total non-current assets		11 820	14 188
TOTAL ASSETS		98 164	93 847
LIABILITIES AND EQUITY
Current liabilities
Current lease liabilities		593	2 519
Trade and other payables	6	3 849	5 506
Tax liabilities		2 534	1 267
Total current liabilities		6 976	9 292
Non-current liabilities
Non-current lease liabilities		3 966	3 389
Non-current provisions		45	45
Total non-current liabilities		4 011	3 434
Total liabilities		10 987	12 726
Equity
Share capital	7	3 600	3 600
Share premium		4 967	4 967
Statutory reserve capital		1 306	1 306
Unrealised exchange rate differences		-19 875	-18 949
Retained earnings		92 340	85 844
Total equity attributable to equity holders of the Parent company		82 338	76 768
Non-controlling interest		4 839	4 353
Total equity		87 177	81 121
TOTAL EQUITY AND LIABILITIES		98 164	93 847

Consolidated Income Statement

in thousands of EUR	Note	3Q 2026	3Q 2025	09m 2026	09m 2025
		Unaudited	Unaudited	Unaudited	Unaudited
Revenue from contracts with customers	9	16 132	15 951	44 722	44 379
Cost of goods sold		-6 807	-6 812	-19 505	-20 149
Gross Profit		9 325	9 139	25 217	24 230
Distribution expenses		-3 569	-3 431	-10 481	-9 661
Administrative expenses		-1 422	-1 328	-4 506	-4 000
Other operating income		133	102	343	260
Other operating expenses		-132	-185	-487	-571
Operating profit		4 335	4 297	10 086	10 258
Currency exchange income/(expense)		-850	-701	-698	737
Other finance income/(expenses)		256	133	548	347
Net finance income		-594	-568	-150	1 084
Profit (loss) from associates using equity method		2	-1	-2	-13
Profit before tax		3 743	3 728	9 934	11 329
Income tax expense		-1 019	-1 022	-2 889	-2 344
Profit for the period		2 724	2 706	7 045	8 985
Attributable to:
Equity holders of the Parent company		2 535	2 500	6 496	8 281
Non-controlling interest		189	206	549	704
Earnings per share from profit attributable to equity holders of the Parent company, both basic and diluted (EUR)	8	0,07	0,07	0,18	0,23

Consolidated Statement of Comprehensive Income

in thousands of EUR	Note	3Q 2026	3Q 2025	09m 2026	09m 2025
		Unaudited	Unaudited	Unaudited	Unaudited
Profit for the period		2 724	2 706	7 045	8 985
Other comprehensive income (loss) that will be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign operations		-1 844	-764	-989	455
Total other comprehensive income for the period		-1 844	-764	-989	455
Total comprehensive income (loss) for the period		880	1 942	6 056	9 440
Attributable to:
Equity holders of the Parent company		859	1 820	5 570	8 679
Non-controlling interest		21	122	486	761

Consolidated Statement of Cash Flows

in thousands of EUR	Note	09m 2026	09m 2025
Cash flow from operating activities		Unaudited	Unaudited
Profit for the period		7 045	8 985
Adjustments for:
Depreciation and amortization of non-current assets		2 704	2 552
Share of profit of equity accounted investees		2	13
Gains/Losses on the sale of property, plant and equipment		7	1
Net finance income / costs		150	-1 084
Provision for impairment losses on trade receivables		-1	1
Provision for inventories		-24	4
Income tax expense		2 889	2 344
Change in inventories		4 928	-1 339
Change in trade and other receivables		-601	-329
Change in trade and other payables		-788	-2 417
Interest paid		0	-7
Income tax paid		-1 778	-1 858
Net cash flow from operating activities		14 533	6 866
Cash flow from investing activities
Interest received		1 275	1 011
Dividends received		0	12
Purchase of other financial investments		-52 000	-50 400
Proceeds from other financial investments		51 100	44 700
Proceeds from disposal of property, plant and equipment		49	1
Loans granted		0	-11
Proceeds from repayments of loans granted		0	11
Acquisition of property, plant and equipment		-164	-562
Acquisition of intangible assets		-36	-38
Net cash flow from investing activities		224	-5 276
Cash flow from financing activities
Proceeds from borrowings		0	500
Repayment of borrowings		0	-500
Payment of principal portion of lease liabilities		-2 199	-1 847
Interest paid on lease liabilities		-622	-660
Net cash flow from financing activities		-2 821	-2 507
Net increase/decrease in cash and cash equivalents		11 936	-917
Cash and cash equivalents at the beginning of period	2	6 639	7 683
Effect of translation to presentation currency		-1 574	1 321
Effect of exchange rate fluctuations on cash held		-95	-423
Cash and cash equivalents at the end of period	2	16 906	7 664

AS Silvano Fashion Group
Phone: +372 6845 000
Email: info@silvanofashion.com

Attachment

• SFG consolidated interim financial report for Q3 and 09m 2026 unaudited

Regulated Information

Issy-les-Moulineaux, October 30, 2026

Availability of the Fiscal 2026 Universal Registration Document

Sodexo’s Fiscal 2026 Universal Registration Document (URD) was filed with the Autorité des marchés financiers (AMF) in ESEF format on October 30, 2026.

In accordance with applicable regulations, the Universal Registration Document is available on Sodexo’s website (www.sodexo.com > Investors > Financial Results and Publications) and on the AMF’s website
(www.amf-france.org).

This Universal Registration Document includes, in particular:

• the statutory financial statements of Sodexo S.A. for Fiscal 2026;
• the consolidated financial statements of the Group for Fiscal 2026;
• the related auditors’ reports on the statutory and the consolidated financial statements as well as the special report on related-party agreements;
• the management report comprises especially information relating to corporate governance and information relating to sustainability;
• information regarding internal control and risk management;
• the presentation of the resolutions as well as the resolutions submitted to the Combined Shareholders Meeting of December 16, 2026;
• information on the fees paid to the Statutory Auditors; and
• information on the share buyback program.

About Sodexo

Founded in Marseille in 1966 by Pierre Bellon, Sodexo is the leader in Food and Services, shaping better everyday experiences at every moment in life: work, heal, learn and play. The Group stands out for its independence, its founding family shareholding and its responsible business model. With its services, Sodexo meets all the challenges of everyday life with a dual goal: to improve the quality of life of our employees and those we serve, and contribute to the economic, social and environmental progress in the communities where we operate. For Sodexo, growth and social commitment go hand in hand. Our purpose is to create a better everyday for everyone to build a better life for all. Sodexo is included in the CAC Next 20, Bloomberg France 40, CAC SBT 1.5, FTSE 4 Good and DJSI indices.

Key Figures

24 billion euros Fiscal 2026 consolidated revenues 443,000 employees as at August 31, 2026 #1 France-based private employer worldwide

43 countries 80 million consumers served daily 8.3 billion euro in market capitalization (as at October 22, 2026)

Contacts

Investor Relations	Corporate Legal
Juliette KLEIN +33 1 57 75 80 27 juliette.klein@sodexo.com	Olivia GUILLAUME +33 6 15 20 99 48 olivia.guillaume@sodexo.com

Attachment

• Sodexo – Fiscal 2026 URD available (1)

• First FDA-approved biologic specifically designed to cross blood-brain barrier wins award dedicated to exceptional scientific leadership and transformational impact on patient care
• First new FDA-approved treatment option in nearly 20 years for families living with Hunter syndrome, a rare neurodegenerative disorder
• Denali’s brain delivery technology establishes foundation for potential therapies across wide range of diseases that impact the brain, including Alzheimer’s disease

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH^® (tividenofusp alfa-eknm) has been recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation. AVLAYAH is the first biologic approved by the U.S. Food and Drug Administration (FDA) that is specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. AVLAYAH is an enzyme replacement therapy that received FDA accelerated approval in March 2026 for the treatment of neurologic manifestations of a rare neurodegenerative disease called Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory study.

The Galien Foundation, which fosters and recognizes excellence in scientific innovation that improves the state of human health, presented the 2026 Prix Galien USA “Best Biotechnology Product” award to Denali Therapeutics during a ceremony last night at the American Museum of Natural History in New York City. Prix Galien USA Awards are among the highest honors in the global biopharmaceutical industry, acknowledging the most impactful treatments approved by the FDA within the last five years. Prix Galien winners are selected by committees of the top leaders in science and medicine.

“We are honored to receive the Best Biotechnology Product Award for AVLAYAH, which is a culmination of years of pioneering research to solve the challenge of delivering biologics across the blood-brain barrier with our TransportVehicle technology,” said Ryan Watts, Ph.D., co-founder and Chief Executive Officer of Denali Therapeutics. “This recognition also belongs to the Hunter syndrome community and the families, advocates and clinicians whose determination and commitment made AVLAYAH possible. An FDA-approved medicine that reaches the brain offers transformative possibilities for this community, and it is proof that we can bring the power of biologic medicines to the brain for rare genetic diseases and common neurodegenerative disorders that affect millions of people worldwide.”

Denali’s proprietary TransportVehicle™ technology binds to the transferrin receptor (TfR) and is designed to deliver enzymes, antibodies and oligonucleotides to the whole body, including the brain, through receptor-mediated transcytosis. AVLAYAH is the first and only FDA-approved TfR-enabled medicine engineered to specifically cross the blood-brain barrier.

Denali Therapeutics is advancing a growing portfolio of TransportVehicle-enabled therapeutic candidates across all stages of development, including zafinofusp alfa, an investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A), and two investigational medicines for Alzheimer’s disease (AD) that target the two defining pathologies of the disease. DNL628 (OTV:MAPT) is an Oligonucleotide TransportVehicle-enabled antisense oligonucleotide designed for systemic delivery across the blood-brain barrier to reduce tau by targeting the MAPT gene for the treatment of AD. DNL921 (ATV:Abeta) is an Antibody TransportVehicle-enabled antibody designed for systemic delivery across the blood-brain barrier to target amyloid plaques in AD.

About Hunter Syndrome (MPS II)

Hunter syndrome, also known as MPS II, is a rare genetic lysosomal storage disorder that primarily affects boys and impacts approximately 500 individuals in the United States and 2,000 individuals worldwide. The disease is caused by mutations in the iduronate 2-sulfatase (IDS) gene that results in a deficiency of the IDS enzyme, which is responsible for breaking down glycosaminoglycans (GAGs) such as heparan sulfate and dermatan sulfate. The accumulation of GAGs leads to progressive damage in multiple organs and tissues, including the brain. Symptoms of Hunter syndrome include developmental delays, cognitive decline, behavioral abnormalities and physical complications such as joint stiffness, hearing loss and organ dysfunction.

About AVLAYAH® (tividenofusp alfa-eknm)

AVLAYAH (tividenofusp alfa-eknm) is an intravenous enzyme replacement therapy composed of the iduronate 2-sulfatase (IDS) enzyme fused to Denali’s proprietary TransportVehicle™ (TV) platform. The Fc component of AVLAYAH binds to the apical domain of the transferrin receptor (TfR) and delivers IDS to peripheral tissues and to the central nervous system through receptor-mediated transcytosis across the blood-brain barrier. AVLAYAH is internalized via binding to the mannose-6-phosphate receptor on the cell surface and transported into lysosomes where it is thought to exert enzymatic activity and reduce accumulated glycosaminoglycans (GAGs). In addition, since TfR is ubiquitously expressed, it is expected that the interaction of AVLAYAH and TfR will contribute to its uptake into cells in the brain and peripheral tissues. In addition to Rare Pediatric Disease Designation and Breakthrough Therapy Designation, the U.S. Food and Drug Administration granted Fast Track and Orphan Drug designations to AVLAYAH for the treatment of MPS II.

The European Medicines Agency has granted Priority Medicines designation to tividenofusp alfa. AVLAYAH is not approved by health authorities outside of the U.S.

AVLAYAH U.S. Indication

AVLAYAH is approved for the treatment of neurologic symptoms in pediatric patients weighing at least 5 kg with Hunter syndrome prior to advanced neurologic disease. This approval is based on a reduction of heparan sulfate (HS) in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord. Studies are ongoing to confirm how well it works in improving clinical symptoms.

Limitations of Use

AVLAYAH is not recommended for use in combination with other enzyme replacement therapies.

Important Safety Information

AVLAYAH may cause serious side effects, including:

Hypersensitivity Reactions including Anaphylaxis. Life-threatening allergic reactions occurred both early in treatment and after many doses over time, including:

• Fast heartbeat
• Dizziness or fainting
• Wheezing
• Vomiting
• Hives
• Swelling of the lips and tongue

Notify your healthcare provider immediately if these symptoms occur. If a serious allergic reaction happens, your treatment will be stopped and emergency treatment will be given, including use of epinephrine.

Infusion-Associated Reactions (IARs). IARs occurred during or within 24 hours after receiving AVLAYAH, including:

• Chills
• Swelling
• Low blood pressure (dizziness or fainting)
• Fast heartbeat
• Hives
• Wheezing
• Fever
• Flushing or reddening of the skin
• Rash
• Cough
• Diarrhea
• Abdominal pain
• Vomiting
• Headache
• Irritability
• Small bumps on the skin

If you have an IAR, your doctor may slow down, pause, adjust your dose, or stop the infusion depending on how serious the reaction is. You may also be given medicine before infusions to help prevent these reactions. Patients with heart or lung problems may be at higher risk of serious complications from these reactions and will be monitored closely.

Anemia (Low Red Blood Cell Count) occurred during AVLAYAH treatment and may require periodic laboratory tests for hemoglobin. Contact your healthcare provider if you experience any symptoms (e.g., fatigue, pale skin) suggestive of anemia.

Membranous Nephropathy (Kidney disorder that affects the filters that help remove wastes and fluids from the kidney) occurred in an AVLAYAH-treated patient. Your doctor will monitor your kidney function during treatment.

The most common side effects (in 20% or more of patients):

• Infusion-associated reactions
• Upper respiratory infections
• Ear infection
• Fever
• Anemia (low red blood cell count)
• Cough
• Vomiting
• Diarrhea
• Rash
• COVID-19
• Runny or congested nose
• Falls
• Headache
• Skin injuries
• Hives

Contact your healthcare provider right away if you experience any side effects. These are not all the possible side effects of AVLAYAH. You may report side effects to FDA at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Denali Therapeutics at 1-833-ONE-DNLI (1-833-663-3654).

Please see the full Prescribing Information, including Boxed Warning, here for additional Important Safety Information.

About the Denali TransportVehicle^™ Platform

The blood-brain barrier (BBB) is essential in maintaining the brain’s microenvironment and protecting it from harmful substances and pathogens circulating in the bloodstream. Historically, the BBB has posed significant challenges to drug development for central nervous system diseases by preventing most drugs from reaching the brain in therapeutically relevant concentrations. Denali’s TransportVehicle™ (TV) platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes and oligonucleotides throughout the whole body, including the brain, by crossing the BBB after intravenous administration. The TV platform is based on engineered Fc domains that bind to specific natural transport receptors, such as transferrin receptor and CD98 heavy chain amino acid transporter, which are expressed at the BBB and deliver the TV and its therapeutic cargo to the brain through receptor-mediated transcytosis. In animal models, antibodies and enzymes engineered with the TV platform demonstrate more than 10- to 30-fold greater brain exposure than similar antibodies and enzymes without this technology. Oligonucleotides engineered with the TV platform demonstrate more than a 1,000-fold greater brain exposure in primates than systemically delivered oligonucleotides without this technology. Improved exposure and broad distribution in the brain may increase therapeutic efficacy by enabling widespread achievement of therapeutically relevant concentrations of product candidates. The TV platform has been clinically validated, with AVLAYAH® (tividenofusp alfa-eknm) as the first FDA-approved medicine leveraging transferrin receptor to cross the BBB.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali’s TransportVehicle™ (TV) platform, including its therapeutic and commercial potential and its potential to enable therapies across a wide range of diseases that impact the brain; AVLAYAH^® (tividenofusp alfa-eknm), including its therapeutic potential and the likelihood that confirmatory studies will verify clinical benefit and support continued approval; plans, timelines and expectations related to zafinofusp alfa, DNL628, DNL921 and Denali’s other TV-enabled product candidates; and statements by Denali’s Chief Executive Officer. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties. These include, but are not limited to, risks arising from adverse economic conditions and their impact on Denali’s business and operations; Denali’s ability to complete the development and, if approved, the commercialization of product candidates; reliance on third-party manufacturers and suppliers for clinical trial and commercial materials; difficulties enrolling patients for ongoing and future clinical trials; potential delays or failures in meeting expected clinical trial timelines; discrepancies between preclinical, early-stage or preliminary clinical results and later-stage trial outcomes; the risk that interim or topline clinical results may not be predictive of final study results or longer-term outcomes; the risk that the FDA may not accept the data or surrogate endpoints Denali intends to use to support accelerated approval, may require additional or different studies, or may withdraw an accelerated approval if confirmatory studies do not verify clinical benefit; significant adverse events or other undesirable side effects; the uncertainty surrounding regulatory approvals required for commercialization in the U.S., Europe or other international jurisdictions, including uncertainties related to the FDA’s policies; developments relating to Denali’s competitors and competing product candidates; Denali’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; the implementation and success of Denali’s strategic plans for its business, product candidates and blood-brain barrier platform technology; Denali’s ability to obtain additional capital to finance its operations, as needed; Denali’s ability to accurately forecast future revenues and operating expenses in the current environment; quarterly variability in net product revenue and the risk that revenue growth may not continue at recent rates; and other risks and uncertainties, including those described in Denali’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2026, its Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026, and Denali’s future SEC filings. Except for AVLAYAH, Denali’s product candidates are investigational, and their safety and efficacy profiles have not yet been established. Denali undertakes no obligation to update or revise any forward-looking statements, to conform these statements to actual results or reflect changes in Denali’s expectations, except as required by law.

Investor Contact:

Laura Hansen, Ph.D.

hansen@dnli.com

Media Contact:

Erin Patton

epatton@dnli.com

Today, 30 October 2026, AS Tallinna Vesi reached out-of-court settlement with Aktsiaselts Tallinna Sadam in the water price difference dispute. The parties have entered into settlement agreement pursuant to which the claimant will withdraw their claim.

This settlement follows the earlier out-of-court resolution of the disputes with Tallinn University of Technology, Aktsiaselts Olerex, EfTEN SPV2 OÜ, EfTEN Sky OÜ and Kadrioru Ärikeskus OÜ. Tallinna Vesi seeks to resolve all remaining court cases related to water price difference claims from the previous decade on similar principles.

Under the agreement, Aktsiaselts Tallinna Sadam will discontinue their claim, while Tallinna Vesi will make settlement payment of €302,555, an amount broadly equivalent to 50% of the claimant’s principal claim and will reimburse the agreed ancillary costs and legal costs.

According to Taavi Gröön, Chief Financial Officer of Tallinna Vesi, the settlement allows the Company to focus fully on its core activities. “We have reached agreements with a significant proportion of the claimants to resolve the disputes, and our aim is to settle the remaining court cases dating back to the previous decade. This will help avoid further years of litigation and additional costs, allowing us to focus our attention and resources on delivering an essential water service and supporting the Company’s long-term development,” said Gröön. He added that the company has always provided consumers with stable, high-quality water service.

The costs associated with the settlement will be covered by provisions established in previous reporting periods.

Taavi Gröön
Chief Financial Officer
AS Tallinna Vesi
(372) 62 62 200
kommunikatsioon@tvesi.ee

BRISTOL, R.I., Oct. 30, 2026 (GLOBE NEWSWIRE) — KVH Industries, Inc. (Nasdaq: KVHI), will announce its financial results for the third quarter that ended on September 30, 2026, on Thursday, November 5, 2026. In conjunction with the release, the company will conduct its investor conference call at 9:00 a.m. ET, hosted by Mr. Brent Bruun, CEO, and Mr. Anthony Pike, CFO.

A live broadcast of the call will be available online at investors.kvh.com. In addition, an audio replay of the conference call will be available on the website for at least two weeks. To listen to the replay, visit investors.kvh.com starting three hours following the conclusion of the call. Investors who wish to submit questions during or following the call may do so to IR@kvh.com.

About KVH Industries, Inc.

KVH Industries, Inc. is a global leader in maritime and mobile connectivity delivered via the KVH ONE^® network. The company, founded in 1982, is based in Bristol, RI, and has more than a dozen offices around the globe. KVH provides connectivity solutions for commercial maritime, leisure marine, military/government, and land mobile applications on vessels and vehicles, including the TracNet^®, TracPhone^®, and TracVision product lines, the KVH ONE OpenNet Program for non-KVH antennas, AgilePlans^® Connectivity as a Service (CaaS), and the KVH Link crew wellbeing content service.

Contact:	Anthony Pike
	Chief Financial Officer
	KVH Industries, Inc.
	401-847-3327
	apike@kvh.com

Covers approximately 12.9 acres, advancing proposed expansion of Vivakor’s energy infrastructure platform

Dallas, TX, Oct. 30, 2026 (GLOBE NEWSWIRE) — Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), an integrated provider of energy transportation, storage, reuse and remediation services, today announced receipt of a signed, nonbinding letter of intent (“LOI”) from the operator of a major Texas international airport, to negotiate a lease for approximately 12.9 acres at the airport for a proposed hydrogen production plant and fueling station.

The proposed development would expand Vivakor’s energy infrastructure platform into airport fueling services. The October 14, 2026 LOI also allows for consideration of additional land if necessary.

Vivakor envisions a phased development, beginning with hydrogen and compressed natural gas (“CNG”) fueling infrastructure. The proposed facility would support the airport operator’s planned acquisition of 10 hydrogen-powered buses while providing CNG fueling capabilities for its existing vehicles. Additional airport transportation and airline ground support vehicles represent potential future applications.

A second phase would involve the proposed development of an on-site hydrogen production plant using airport-generated organic waste, including food waste and sewage sludge, as potential feedstock. The concept would connect waste generated by airport operations with hydrogen fuel used in those same operations, creating opportunities to expand production and distribution as demand develops.

The proposed project would extend Vivakor’s environmental services strategy into an additional transportation fuel market, building on the resource recovery focus of its Remediation Processing Center initiative.

“This is a significant new opportunity that our team has been working to advance for some time,” said James H. Ballengee, Chairman and Chief Executive Officer of Vivakor. “The proposed development connects an initial airport fueling need with our longer-term vision of recovering value from waste to produce transportation fuel. We look forward to working with the airport operator to advance lease discussions, site planning and required approvals.”

The proposed lease and development remain subject to negotiation of definitive agreements, Federal Aviation Administration (“FAA”) approval, required airport reviews and written approvals, and compliance with applicable local, environmental and safety requirements.

About Vivakor, Inc.

Vivakor, Inc. is an integrated provider of sustainable energy transportation, storage, reuse, and remediation services. Its corporate mission is to develop, acquire, accumulate, and operate assets, properties, and technologies in the energy sector. Vivakor’s integrated facilities assets provide crude oil, storage, transportation, reuse, and remediation services under long-term contracts. Once operational, Vivakor’s interest in oilfield waste remediation facilities will facilitate the recovery, reuse, and disposal of petroleum byproducts and oilfield waste products.

Cautionary Statement Regarding Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. Forward-looking statements may be identified but not limited by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, but not limited to, the expected transaction and ownership structure, the valuation of the transaction, the likelihood and ability of the parties to successfully and timely consummate planned acquisitions, the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect Vivakor or the expected benefits of the such transaction, our ability to maintain the listing of our securities on The Nasdaq Capital Market, the parties failure to realize the anticipated benefits of pending transactions, disruption and volatility in the global currency, capital, and credit markets, changes in federal, local and foreign governmental regulation, changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, and general economic conditions.

These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor’s filings with the U.S. Securities and Exchange Commission, which factors may be incorporated herein by reference. Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. All information set forth herein speaks only as of the date hereof in the case of information about Vivakor or the date of such information in the case of information from persons other than Vivakor, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication. Forecasts and estimates regarding the industries and markets are based on sources we believe to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

Investor Contact:
P:469-480-7175
info@vivakor.com

An Equipment Innovator’s Interest in Kraig’s High Tech Fibers Indicates Potential Applications for Lightweight and/or Tough Materials, and Possibly Elevate Project Atlas

DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) — (www.247marketnews.com)— Kraig Biocraft Laboratories (OTCQB: KBLB) has put its recombinant spider silk in the hands of a company with experience developing materials alongside major aerospace manufacturers. The shipment opens an intriguing avenue for a biological fiber whose combination of strength, flexibility, and toughness has long attracted engineering interest.

In its October 26 announcement, Kraig said the unnamed recipient that requested the samples is known for developing advanced yarn-spinning equipment. The company also launched a program to create new yarn constructions and material blends for fabrics, apparel, and other applications.

The development follows Kraig’s September delivery of custom spider-silk yarn to a globally recognized performance sports brand. That order was processed to the customer’s specifications for a particular performance-textile application, establishing a commercial starting point for the company’s broader materials ambitions.

We are still waiting to know who received it, how it did and what they made with it!

The recent recipient’s aerospace background makes that sector a credible area for exploration. A specific aerospace application or contract has not been disclosed. Knowing what Spider Silk can do may open up many more possibilities.

“Spider silk is a material that will earn its place through performance,” Kraig founder and CEO Kim Thompson said in the October 26 announcement.

Understanding that performance begins with the distinction between strength and toughness.

• Tensile strength measures how much pulling stress a material can withstand.
• Toughness measures the energy it absorbs before breaking.

Spider silk’s ability to carry a substantial load while stretching gives it an unusual combination of both.

Darwin’s bark spider offers a striking natural benchmark. In the original study of its silk, forcibly collected fibers averaged approximately 350 megajoules per cubic meter in toughness, with individual samples reaching 520. Its exceptional ability to absorb energy helped establish the species as an important subject for advanced-materials research.

For aerospace engineers, that combination suggests possibilities in lightweight materials designed to tolerate impact and damage.

The interest already has an industry precedent. In 2018, Airbus announced work with biomaterials company AMSilk to explore artificial spider-silk composites. Airbus identified flexibility and shock resistance as reasons to investigate the material, including potential uses in aircraft areas exposed to debris or bird strikes and protection for space equipment. Those were research objectives, providing a concrete example of why aerospace developers have considered silk-based materials.

One promising approach is to combine silk with other reinforcing fibers. Carbon fiber offers high stiffness and strength; silk could contribute additional energy absorption. Adjusting the combination could help engineers balance the properties needed for a particular component.

A 2019 study demonstrated that principle using wild silkworm silk and carbon fiber in epoxy composites. One hybrid configuration achieved approximately twice the impact strength of the carbon-fiber composite tested alongside it. Increasing the silk content favored impact performance, while more carbon fiber generally favored stiffness and strength. The experiment used Antheraea pernyi silk, offering evidence for the hybrid-material approach rather than a measurement of Kraig’s recombinant fibers.

Project Atlas adds a further possibility to Kraig’s development path.

In January 2025, Kraig Labs announced that its researchers had incorporated key genetic sequences derived from Darwin’s bark spider silk proteins into engineered silkworms. The approach connects an exceptional natural material with a production system based on established silkworm cultivation.

In September 2026, Kraig reported completing the foundational Project Atlas Gene Library, establishing every planned Atlas transgene in living commercial silkworm hosts. The next phase focuses on stable breeding lines and evaluating more than 200 potential genetic configurations. The company’s stated objectives include enhanced strength, toughness, and flexibility, ultimately combining the full suite of Atlas genetics in a production strain.

If Atlas produces fibers approaching the toughness of natural Darwin’s bark spider silk, it could expand the range of demanding applications worth pursuing. The decisive evidence would be the measured properties of those fibers and how well their performance carries through into finished yarns and composites.

That is where the new yarn-development program becomes particularly relevant. Genetics can influence the proteins within a fiber, while yarn construction and blending help determine how the fiber performs in a usable material. An equipment specialist’s involvement could help connect those stages.

For Kraig, the opportunity is to develop materials around specific customer needs, with both biological design and textile engineering contributing to the result. Its commercial yarn delivery provides a starting point. The latest sample shipment brings relevant industrial expertise into the picture. Atlas could eventually supply a new generation of fibers for that work.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit www.247marketnews.com or https://go.247marketnews.com/kblb-disclosure/

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

500 Patients, 30 Hospitals, 3 Countries is Part of the Setup

DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) — (247MarketNews.com) — In a market where the latest whizbang trends often dominate investor attention, NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing something considerably more meaningful: advancing potential treatments for some of the most difficult-to-treat brain cancers while building a clinical development program that could eventually reach hundreds of patients internationally.

Now, the company is putting some impressive numbers behind that ambition.

During its appearance on Health Uncensored with Dr. Drew on Fox Business Network, NeOnc outlined plans for a pivotal clinical trial targeting approximately 500 patients across 30 hospitals in three countries. The proposed expansion represents a substantial step forward for a company seeking to address one of oncology’s most persistent challenges: getting potential treatments where they need to go inside the human brain.

For the market, the story brings together several potentially important ingredients: an innovative drug-delivery approach, encouraging but preliminary clinical observations, two investigational drug programs, international development ambitions, and a potentially intriguing stock-market setup involving substantial short interest.

The science is the foundation, the patients are the reason, and the possibility that Wall Street could eventually take notice adds another dimension to the story.

A 500-Patient Ambition That Changes the Conversation

A proposed clinical trial involving approximately 500 patients across 30 hospitals in three countries is not a small undertaking.

It represents a planned expansion of NeOnc’s clinical ambitions and an opportunity to investigate its treatment approach in a much larger patient population, as the scale of the proposal signals where management wants to take the program.

At the center of that effort is NEO100, NeOnc’s investigational treatment being evaluated for its potential role in brain cancer.

The challenge it seeks to address is formidable. The blood-brain barrier serves as the brain’s natural protective defense system, but that protection also creates a major obstacle for drug developers. Many potential therapies struggle to reach tumors in sufficient concentrations because of this biological barrier.

NeOnc is investigating a different approach.

Its NEO100 program uses intranasal administration, designed to deliver therapy through the nasal pathway toward the brain while bypassing the blood-brain barrier.

In other words, the company isn’t simply investigating what treatment might work. It is also investigating how to get that treatment where it needs to go.

That distinction could be important in a field where drug delivery remains one of the biggest obstacles to therapeutic progress.

Early Clinical Observations Give the Story a Foundation

The proposed international expansion comes against the backdrop of earlier clinical observations that have attracted attention.

In its December 2025 clinical update, NeOnc described significant radiographic remission in six of 25 patients across its combined clinical and compassionate-use experience, representing approximately 24%.

For a company pursuing treatments for difficult brain cancers, that is an encouraging observation worth following.

The company’s appearance on Dr. Drew’s program also brought the patient experience into the conversation.

One patient described reaching two years on therapy and reported tolerating treatment without reactions. During the discussion, when Dr. Drew asked about the tumor’s status, physician Dr. Wallace responded, “We can’t see it, actually, at this moment.”

It was a striking moment, illustrating why continued research in this field matters.

For families facing aggressive brain cancer, the objective isn’t simply another clinical milestone or a better number on a presentation slide. It is more time together. Another birthday. Another anniversary. Another opportunity to experience everyday life.

Those individual experiences cannot establish clinical efficacy, but they help explain the enormous human stakes behind NeOnc’s research.

More Than One Drug: A Broader Development and Technology Story

NEO100 isn’t the only component of NeOnc’s development strategy.

The company is also advancing NEO212, which completed its Phase 1 dose-escalation work. A November 17 FDA meeting is scheduled for an important regulatory discussion concerning potential Phase 2 development, including study design, patient population, dosing and endpoints.

Together, the two programs give NeOnc multiple development milestones to pursue.

The company’s ambitions also extend beyond conventional drug development.

Its research platform combines patented 3D bioprinting technology with artificial intelligence to create patient-derived tumor models and help researchers evaluate potential treatments.

This approach could support a more personalized understanding of tumor biology and treatment response.

The company has also highlighted molecular characteristics, including IDH mutations, as part of its precision-medicine strategy.

For investors, the broader takeaway is that NeOnc is building a story around multiple interconnected capabilities: drug development, innovative delivery, tumor modeling and AI-assisted research.

Meanwhile, its international ambitions have been reinforced by developments in Abu Dhabi, including the appointment of Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to the company’s board.

These developments add an international dimension to a company whose clinical ambitions are increasingly extending beyond a single market.

Now Comes the Interesting Part for Traders: Potential Short Squeeze

While the clinical story is compelling on its own, NTHI also has another ingredient that could make its shares particularly interesting to traders: short interest.

Based on the October 15 Nasdaq market-data, approximately 877,000 shares were reported short.

At the same time, the stock has recovered from an approximate $2.50 low to eclipse the $3 level.

Put those figures together and the potential trading implications become interesting.

The reported short position represents approximately 5.6 days of trading volume at that ten-day average. If short sellers needed to cover 500,000 shares over a relatively short period, that would represent more than three full days of average trading volume. That is a meaningful amount of potential buying demand.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB)

Combines Two Complementary Platforms Across Therapeutic Modalities: Castle Creek’s Fibroblast-Based Cell and Gene Therapy Technology with Pelthos’ Novel Platform

DURHAM, N.C. and EXTON, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos” or the “Company”), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, and Castle Creek Biosciences, Inc. (“Castle Creek”), a late-stage company developing redosable gene therapies, today announced they have entered into a definitive agreement under which Castle Creek will merge with Pelthos. The combination creates a transformative biotechnology company with novel technologies, including cell and gene therapy, targeting serious diseases that affect the skin. Castle Creek’s late-stage fibroblast-based platform complements Pelthos’ novel FDA-approved product portfolio and established commercial capabilities in dermatology. Upon close, the combined company will operate as Pelthos Therapeutics Inc. and continue to trade on the NYSE American (ticker symbol: “PTHS”).

Castle Creek’s lead candidate is D-Fi (dabocemagene autoficel; FCX-007), an injectable, redosable, gene-modified cell therapy with a continued Phase 3 study planned for the treatment of dystrophic epidermolysis bullosa (DEB), a devastating rare inherited disease caused by mutations in the COL7A1 gene. There is significant demand for new treatment options in DEB given the substantial burden of untreated wounds and increased risk of squamous cell carcinoma. D-Fi, which has received Orphan Drug Designation, is administered by intradermal injection every other month, and the drug product delivers type VII collagen (COL7) producing cells. In addition, Castle Creek is using its proprietary fibroblast technology to develop a topical formulation of D-Fi and to pursue additional therapeutic targets in serious diseases that affect the skin, including malignancies and inflammatory conditions.

“This transformative combination brings a novel platform with significant growth potential to Pelthos and broadens our focus beyond cutaneous infectious diseases to serious diseases that affect the skin,” said Scott Plesha, CEO of Pelthos. “D-Fi builds on our established strength in dermatology, especially within pediatric dermatology, which we believe will accelerate its launch and value in the marketplace. This transaction creates a stronger, more diversified biotechnology company positioned to bring important new therapies to patients and drive long-term value for our shareholders.”

“D-Fi has the potential to become a blockbuster franchise in DEB, where patients still have significant unmet needs,” said Matt Gantz, Chairman and CEO of Castle Creek. “Joining with Pelthos will provide the commercial infrastructure to help realize the D-Fi opportunity and accelerate the pipeline of new indications from our platform.”

Strategic Rationale

• Compelling Complementary Capabilities: As part of Pelthos’ portfolio, D-Fi will leverage the Company’s established commercial leadership, deep expertise in dermatology, and existing physician relationships to accelerate its commercial launch and delivery of important therapies to patients.
• Greater Pipeline Diversification: The combination brings together Pelthos’ three novel FDA-approved products, ZELSUVMI^®, XEPI^® and XEGLYZE^®, with D-Fi, creating a portfolio spanning marketed, launch-stage and late-stage assets across multiple therapeutic modalities. This broader mix provides multiple potential sources of growth over different time horizons.
• Expanded Technology Base: Castle Creek’s fibroblast technology adds a cell and gene therapy capability to Pelthos’ existing Nitricil platform, giving the combined company multiple therapeutic modalities to address serious diseases that affect the skin where conventional small molecules have had limited impact and expand the pipeline over time.

Transaction Terms

Under the terms of the agreement, Castle Creek stockholders will receive 5,200,000 shares of Pelthos common stock at the closing of the transaction, representing approximately 32.5% of Pelthos’ fully diluted shares. As defined within the agreement, and subject to meeting various developmental and sales-based criteria, Castle Creek stockholders will also be eligible to receive: (i) up to 5,800,000 shares of Pelthos common stock upon FDA approval of D-Fi; (ii) up to a total of $300 million in milestone payments, payable in cash (or, to the extent required to preserve the intended tax treatment of the transaction, in a combination of cash and shares of Pelthos common stock), including a $50 million payment due upon achievement of specified Phase 3 clinical endpoints, and up to $250 million in additional consideration tied to D-Fi’s first commercial sale and achievement of specified net sales milestones; and (iii) 80% of the net proceeds from the sale of any priority review voucher awarded upon FDA approval of D-Fi.

The transaction has been approved by the boards of directors of both companies and is expected to close by the end of the first quarter of 2027, subject to customary closing conditions including approval by Castle Creek’s stockholders. Scott Plesha will continue to serve as Chief Executive Officer, and Peter Greenleaf will serve as Executive Chair of the combined company. Upon closing, the combined company’s board will consist of 10 directors, including two designated by Castle Creek.

Advisors

Latham & Watkins LLP is serving as legal advisor to Pelthos. Oppenheimer & Co. Inc. provided a fairness opinion to Pelthos’ board of directors. Bradley Arant Boult Cummings LLP and Katten Muchin Rosenman LLP are serving as legal advisors to Castle Creek and PHCP, LLC is serving as financial advisor to Castle Creek. Collected Strategies is serving as strategic communications advisor to Pelthos.

About D-Fi
D-Fi (dabocemagene autoficel; FCX-007) is an injectable autologous gene-modified cell therapy candidate for the treatment of DEB, a devastating, progressive, painful and debilitating rare genetic skin disorder. DEB is caused by a mutation in the COL7A1 gene, leading to a deficiency of normal type VII collagen (COL7) protein, impairing the connection between the epidermis and the dermis. D-Fi is composed of a patient’s own dermal fibroblasts, which are genetically modified completely ex vivo with a self-inactivating (SIN) lentiviral vector (LV) containing the COL7A1 gene to express COL7. D-Fi is locally administered by intradermal injection into chronic wounds where the COL7 protein can support the formation of anchoring fibrils in the skin. In clinical studies, D-Fi has been generally well tolerated, with injection site reactions (skin discoloration, erythema, hemorrhage, pain, and swelling) being the most commonly reported adverse drug reactions. D-Fi has Orphan Drug Designation for the treatment of DEB and Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy designations for the treatment of recessive DEB (RDEB) from the FDA.

About Castle Creek Biosciences, Inc.
Castle Creek Biosciences is a late-stage company developing re-dosable gene therapies. It is preparing to advance the Phase 3 program of its lead candidate, D-Fi (FCX-007), for patients with dystrophic epidermolysis bullosa (DEB). Learn more at castlecreekbio.com.

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI^® (berdazimer) topical gel, 10.3%, the Company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The Company’s portfolio of assets includes XEPI^® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE^® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)). These forward-looking statements include, but are not limited to, statements regarding the proposed transaction involving Pelthos and Castle Creek. Forward-looking statements generally include statements that are speculative in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could,” “might,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “seek,” “target,” “potential,” “predict,” “forecast,” “continue,” and other similar expressions or the negative or plural of these words, or other similar expressions that are speculative or indicate future events or prospects. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, expectations regarding the proposed transaction; the potential benefits of the proposed transaction, including the sufficiency of the combined company’s capital resources; the expected timing of the closing of the proposed transaction; statements regarding the potential achievement of, and expectations regarding, Castle Creek’s and Pelthos’s programs, including the potential achievement of any milestone; receipt of FDA approval of D-Fi, issuance of any contingent shares in connection with the proposed transaction or receipt of any priority review voucher; the continued listing of Pelthos on the NYSE American; and the anticipated benefits of the proposed transaction and the combined company’s opportunities, strategy, and plans following the proposed transaction. Forward-looking statements are based on current beliefs and assumptions of management that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation:

• the occurrence of any event, change or other circumstances that could give rise to the termination of the proposed transaction;
• the risk that Pelthos may be unable to obtain governmental and regulatory approvals and clearances required for the proposed transaction, or required governmental and regulatory approvals and clearances may delay the proposed transaction or result in the imposition of conditions that could cause the parties to abandon the proposed transaction;
• risks related to disruption of management time from ongoing business operations due to the proposed transaction;
• the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Pelthos’s common stock;
• the risk of any unexpected costs or expenses resulting from the proposed transaction;
• the risk of any litigation relating to the proposed transaction;
• the risk that the proposed transaction and the related announcement could have an adverse effect on the ability of Pelthos and/or Castle Creek to retain and hire key personnel;
• the risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected;
• the risk that the combined company may be unable to achieve the anticipated benefits of the proposed transaction or it may take longer than expected to achieve those benefits and other important factors that could cause actual results to differ materially from those projected;
• the limited operating history of each company and their significant net losses incurred since inception;
• the need to raise additional capital to finance operations;
• uncertainties related to commercialization or market acceptance of FDA-approved products;
• the ability to advance product candidates through preclinical and clinical development;
• the ability to obtain regulatory approval for, and ultimately commercialize, the combined company’s product candidates;
• the outcome of early clinical trials for product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements;
• the ability of Pelthos, Castle Creek and the combined company to protect their respective intellectual property and proprietary technologies;
• reliance on third parties, contract manufacturers, and contract research organizations;
• the risk that the concurrent private financing is not consummated;
• the risk that the conditions to the closing of the proposed transaction are not satisfied in a timely manner or at all;
• product liability lawsuits, which could cause Pelthos to incur substantial liabilities and limit commercialization of any products that Pelthos may develop;
• current and future healthcare reform legislation or regulation, which may increase the difficulty and cost for Pelthos to commercialize products, may adversely affect the prices Pelthos may obtain and may have a negative impact on Pelthos’ business and results of operations;
• delays or disruptions in the supply chain and manufacturing of Pelthos’ products;
• the seasonal nature of Pelthos’ business;
• the effects of inflation or trade tariffs; and
• market, economic and other conditions, Pelthos’ current liquidity position, Pelthos’ ability to continue as a going concern, to maintain the listing of Pelthos’ common stock on the NYSE American, to manage costs and execute on its operational and budget plans, and to achieve its financial goals.

The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Pelthos’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”). In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than described. Pelthos and Castle Creek can give no assurance that the conditions to the proposed transaction will be satisfied. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All subsequent written and oral forward-looking statements concerning the matters addressed herein and attributable to Pelthos, Castle Creek or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Except as required by applicable law, Pelthos and Castle Creek undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

NO OFFER OR SOLICITATION

This communication is not intended to be, and shall not constitute, an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

IMPORTANT ADDITIONAL INFORMATION AND WHERE TO FIND IT

In connection with the proposed transaction, Pelthos intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will include an information statement and that will also constitute a prospectus of Pelthos. Pelthos may also file other relevant documents with the SEC regarding the proposed transaction. This communication is not a substitute for the information statement/prospectus, registration statement or any other document that Pelthos may file with the SEC. The definitive information statement/prospectus (when available) will be mailed to stockholders of Pelthos. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE INFORMATION STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT MAY BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT PELTHOS, CASTLE CREEK AND THE PROPOSED TRANSACTION.

Investors and stockholders will be able to obtain free copies of the information statement/prospectus and other documents filed by Pelthos with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of the information statement/prospectus (when available) and other documents filed with the SEC by Pelthos may be obtained free of charge on Pelthos’s website at https://ir.pelthos.com/sec-filings/all-sec-filings or, alternatively, by contacting Pelthos at (919)-908-2400 or in writing at Pelthos, 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703. Investors and stockholders are urged to read the information statement/prospectus and the other relevant materials when they become available because they contain important information about the proposed transaction.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
Jude Gorman / Dylan O’Keefe
Collected Strategies
Pelthos-CS@collectedstrategies.com

ATLANTA, GA, Oct. 30, 2026 (GLOBE NEWSWIRE) — Trust Stamp (NASDAQ:IDAI), a global provider of AI-powered software solutions, today announced the signing of a Master Technology Subcontract Agreement with E&P Limited, the Ghanaian company leading the deployment of AFCAS, a public-private partnership with the Ghana National Fire Service to digitise fire compliance and safety certification nationwide. Under the agreement, Trust Stamp is appointed the sole and exclusive technology subcontractor for the AFCAS programme.

AFCAS digitises the full fire safety certification process, from application and payment through inspection to certificate issuance. Under the agreement, Trust Stamp will provide the programme’s core technology and biometric identity layer, integrated with local payment and programme partners. Together this enables verified inspectors, secure digital payments and tamper-resistant certificates that can be checked instantly, helping to reduce fraud, improve revenue collection and make buildings safer. Based on certification volumes projected by E&P, the programme represents a multi-million-dollar ARR opportunity for Trust Stamp, subject to final commercial terms.

All programme data will be stored and processed in Ghana, in line with the Data Protection Act, 2012 (Act 843). Trust Stamp’s patented Irreversibly Transformed Identity Token (IT2) technology transforms sensitive biometric data into secure, revocable identity tokens, enabling trusted verification and fraud prevention while reducing the risks associated with storing biometric data.

Trust Stamp CEO Gareth N. Genner commented, “AFCAS is a strong example of how our technology can help governments modernise essential public services while keeping data sovereign. Following our recent agreement in Nigeria, this appointment further strengthens our position as a trusted identity and digital infrastructure partner across Africa.”

Jonathan Patscheider, SVP Africa at Trust Stamp, added, “E&P has built a compelling programme with the Ghana National Fire Service, and we are proud to be its exclusive technology partner. Digital, verifiable certification makes buildings safer, reduces fraud and improves revenue collection, and we see this model being adopted well beyond Ghana.”

Isaac Obeng-Darko, COO at E&P Limited commented, “Our partnership with Trust Stamp presents a unique opportunity to fully ringfence and secure a nationwide operation that assures all stakeholders of secure identity management. From the outset this partnership deploys the use of world class technology and innovative regulatory activity that provides immense value for the safety of Ghanaian citizens going forward.”

About Trust Stamp

Trust Stamp is a global provider of AI-powered services for use in multiple sectors including banking and finance, regulatory compliance, government, healthcare, real estate, communications, and humanitarian services. Its technology empowers organizations via advanced solutions that ensure technology and data sovereignty, reduce fraud, tokenize and secure assets and data, and securely authenticate users while protecting personal privacy, reducing friction in digital transactions, and increasing operational efficiency. With team members from over twenty nationalities in ten countries across North America, Europe, Asia, and Africa, Trust Stamp trades on the Nasdaq Capital Market (NASDAQ:IDAI).

About E&P Limited

E&P Services Ltd is a major contractor for Engineering and Maintenance services. Their range of services include Above Storage Tanks (AST) & Underground Storage Tanks (UST) Tank Cleaning, Calibration Services, Corrosion Control, Fabrication and Piping, Fuel Treatment and Civil Works. Their scope covers, but not limited to the Petroleum and Mining Industry, Marine Industry, Manufacturing Industry and the Aviation Industry.

Inquiries: shareholders@truststamp.ai

Safe Harbor Statement: Caution Concerning Forward-Looking Remarks 

All statements in this release that are not based on historical fact are “forward-looking statements” including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The information in this announcement may contain forward-looking statements and information related to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events-based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.